Numerous biomarkers have been proposed as prognostic markers in invasive BC; however, stratification of tumors into prognostic groups to guide therapeutic decision is based mainly on tumor stage and grade and on assessment of ER, PR, MIB1 and HER2 status [6]. This evidence concerns the gene PGR and neoplasm.